Technology Platform
The RuCIA Platform
Rudacure Ion Channel Innovative Assessment — the core engine integrating AI-driven molecular prediction with high-throughput electrophysiological validation.
Ion Channel Mastery
Specialized in ion channels governing pain and sensory signals including TRPV1 and TRPA1. AI predicts channel-ligand interactions to discover selective drug candidates.
AI Molecular Simulation
Molecular-level simulation eliminates off-target effects preemptively. Fully resolved the hyperthermia side effect of first-generation TRPV1 antagonists.
Electrophysiology Validation
High-throughput electrophysiology validation using patch clamp technology. Confirms AI predictions against actual ion channel activity data.
CRO Services
Specialized electrophysiology CRO services. Customized efficacy evaluation with animal models for ocular and sensory diseases.
Competitive Advantage
RuCIA vs Traditional Drug Discovery
| Metric | Traditional | RuCIA | Gap |
|---|---|---|---|
| Development Time | 10-15 years | 3-5 years | 70% |
| Candidate Selectivity | Trial & Error | 100% AI-Predicted | — |
| Side Effects (Hyperthermia) | Unresolved | Fully Resolved | — |
| Cost Efficiency | $2.6B Average | Significantly Reduced | — |
Beyond the Signal
Ion channels are key regulators of pain, temperature sensation, and ocular surface homeostasis. RuCIA precisely modulates the source of these signals, treating causes rather than symptoms.
In the post-opioid era, where FDA/EMA prioritize non-addictive alternatives, RudaCure's TRPV1 platform is a strategic partnership target for global pharmaceutical companies.
